Greyledge Technologies Receives $2.5 Million Convertible Loan from Publicly-Traded Lender to Expand Cell Processing Facilities and Data Management Capability
Summary
Greyledge is an industry-leading biotech and emerging growth company specializing in cell therapeutics produced from a patient’s own blood or bone marrow tissue. This latest financing will be used to maximize revenue growth, advance data acquisition capabilities, and broadly expand Greyledge’s cell processing facilities, providing physicians and surgeons with biologic products to support pain control and augmented tissue healing. Dr. Karli states, “With their experience and track record in developing early-phase tech companies, the parent organization of our lender is a strong partner to assist Greyledge in scaling production of our cell therapeutic facilities along with our novel data integration platform to further enhance our ability to optimize applications and the clinical effectiveness of our cell therapy products to an expanding market. Founded in 2010 in Colorado, Greyledge has developed industry leading quality control systems to process biologic therapy products created from a patient’s own blood or bone marrow tissue, used in treating common Orthopedic conditions. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events.